Twitter-enabled Mobile Messaging for Smoking Relapse Prevention (Tweet2Quit)

Trial ID or NCT#



not recruiting iconNOT RECRUITING


Tweet2Quit is an innovative smoking cessation intervention that combines real-time online peer-to-peer support with auto messaging. In a three-group randomized controlled trial, the investigators will compare: 1) usual care, 2) Tweet2Quit-coed, and 3) Tweet2Quit-Women only.

Official Title

Social Media Technology for Treating Tobacco Addiction

Eligibility Criteria

Ages Eligible for Study: 21 Years to 59 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: Yes
Inclusion Criteria:
  1. - Are 21-59 years of age - Are smoking 5+ cigarettes/day and 100+ cigarettes in one's lifetime - In the preparation stage of quitting smoking - Are English speaking - Have a mobile phone with an unlimited texting plan and internet access (via mobile phone) - Text at least once a week - Are a social media user - Have an active email account - Lives in the continental USA
Exclusion Criteria:
  1. - Have certain medical conditions that are contraindicated for nicotine replacement therapy: pregnant, breast feeding, a recent heart attack, an irregular heartbeat, high blood pressure not controlled with medication, skin allergies to adhesive tape or serious skin problems, taking a prescription medicine for depression, and/or any other medical conditions that would prevent you from completing this study. - Are an illicit hard drug user or regular marijuana user - Share a household with someone else or has an immediate family member who has already enrolled in the study currently or in the past or if the participant has already been enrolled or failed to pass the screening once already since October 2016 - Participated in Tweet2Quit between 2012-2013 in a Twitter group and was not an active tweeter (<1 week) - Fails to provide valid forms of all the required personal contact information


Judith Prochaska
Senior Associate Vice Provost, Clinical Research Governance and Professor of Medicine (Stanford Prevention Research Center)

Contact us to find out if this trial is right for you.


Judith J Prochaska, PhD, MPH